1
|
Bhadouria N, Alam A, Kaur A. Unraveling Skin Carcinoma: A Comprehensive Examination of Diagnosis, Treatment Strategies, and Emerging Therapeutic Avenues in Skin Cancer Management. Pharm Nanotechnol 2024; 12:PNT-EPUB-139062. [PMID: 38468531 DOI: 10.2174/0122117385282163240220072251] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2023] [Revised: 02/01/2024] [Accepted: 02/07/2024] [Indexed: 03/13/2024]
Abstract
Cancer that begins in the skin is by far the most common kind of skin cancer found everywhere in the globe. It is further subdivided into groups, such as basal cell carcinoma and cutaneous squamous cell carcinoma, in addition to other, less common types of skin cancer. In this article, the diagnostic aspects that need to be taken into consideration when utilizing these new guidelines, go over the essential features of cutaneous SCC, conduct an analysis of recent changes in the category of cutaneous SCC, and speak about recent advancements in the categorization of cutaneous SCC. Over the course of the past decade, photodynamic therapy has developed into a potentially effective treatment for a variety of solid tumors that may be found in people. The combination of metallic nanoparticles and phytoconstituents as a therapy for skin cancer has the potential to be more successful than each treatment used independently. In this article, the various treatment modalities for skin cancer were examined. This included excision surgery, Mohs surgery, radiation therapy, and immunotherapy. These were then followed by targeted therapy or immunotherapy, in addition to surgery, radiation, or photodynamic therapy. Since excision surgery is the most typical procedure used to eradicate skin cancer, we concentrate on it in particular.
Collapse
Affiliation(s)
- Namrata Bhadouria
- Department of Pharmacy, School of medical and Allied Sciences, Galgotias University Greater Noida, Uttar Pradesh, India
| | - Aftab Alam
- Department of Pharmacy, School of medical and Allied Sciences, Galgotias University Greater Noida, Uttar Pradesh, India
| | - Awaneet Kaur
- Department of Pharmacy, School of medical and Allied Sciences, Galgotias University Greater Noida, Uttar Pradesh, India
| |
Collapse
|
2
|
Tagliaferri L, Ciardo FG, Fionda B, Casà C, DI Stefani A, Lancellotta V, Placidi E, Macchia G, Capocchiano ND, Morganti AG, Kovács G, Bussu F, Peris K, Valentini V. Non-melanoma Skin Cancer Treated by Contact High-dose-rate Radiotherapy (Brachytherapy): A Mono-institutional Series and Literature Review. In Vivo 2021; 35:2313-2319. [PMID: 34182511 PMCID: PMC8286496 DOI: 10.21873/invivo.12505] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2021] [Revised: 05/11/2021] [Accepted: 05/21/2021] [Indexed: 02/07/2023]
Abstract
BACKGROUND/AIM Non-melanoma skin cancers (NMSC) are the most common neoplasms worldwide and their incidence has been proven to increase in recent years and their treatment should aim at cancer cure as well as cosmetic and functional results. The aim of the study was to report the results of our mono-institutional series of high-dose-rate radiotherapy (cHDR-RT) in NMSC, based on a homogenous technique and two different treatment schedules. PATIENTS AND METHODS All patients affected by NMSC who were consecutively evaluated and treated at our Interventional Oncology Center from October 2018 to August 2020, were included. Patients underwent cHDR-RT using flap applicators and remotely afterloaded Ir-192 sources. RESULTS Overall, 51 patients were treated for a total of 67 lesions. Local control (LC) and disease-specific survival (DSS) were 94.0% and 100%, respectively. Grade 1, grade 2, grade 3 and grade 4 acute toxicity rates were 24.6%, 3.5%, 3.5%, and 0.0%, respectively. The cosmetic results were graded as excellent/good, fair, and poor in 73.7%, 19.3%, and 7.0%. CONCLUSION cHDR-RT of NMSC is an effective alternative to surgery due to excellent outcomes both in terms of local control and aesthetic results especially in the face.
Collapse
Affiliation(s)
- Luca Tagliaferri
- U.O.C. Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy
| | | | - Bruno Fionda
- U.O.C. Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy;
| | - Calogero Casà
- U.O.C. Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy
| | - Alessandro DI Stefani
- U.O.C. Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy
- Istituto di Dermatologia, Università Cattolica del Sacro Cuore, Rome, Italy
| | - Valentina Lancellotta
- U.O.C. Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy
| | - Elisa Placidi
- U.O.C. Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy
| | - Gabriella Macchia
- Radiotherapy Unit, Gemelli Molise Hospital, Università Cattolica del Sacro Cuore, Campobasso, Italy
| | - Nikola Dino Capocchiano
- U.O.C. Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy
| | - Alessio Giuseppe Morganti
- Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
- Department of Experimental, Diagnostic and Specialty Medicine-DIMES, Alma Mater Studiorum University of Bologna, Bologna, Italy
| | - György Kovács
- Educational Program Director Gemelli-INTERACTS, Università Cattolica del Sacro Cuore, Rome, Italy
| | - Francesco Bussu
- Divisione di Otorinolaringoiatria, Azienda Ospedaliero Universitaria, Sassari, Italy
- Department of Otorinolaringoiatria, Università degli studi di Sassari, Sassari, Italy
| | - Ketty Peris
- U.O.C. Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy
- Istituto di Dermatologia, Università Cattolica del Sacro Cuore, Rome, Italy
| | - Vincenzo Valentini
- U.O.C. Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy
- Istituto di Radiologia, Università Cattolica del Sacro Cuore, Rome, Italy
| |
Collapse
|
3
|
Hoebers FJP, Ordonez BP, Irish J, Simpson RE, Yu E, O'Sullivan B. Progressive tumefactive fibroinflammatory lesion of the infratemporal fossa treated by radiation therapy. Rare Tumors 2012; 4:e12. [PMID: 22532910 PMCID: PMC3325739 DOI: 10.4081/rt.2012.e12] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2011] [Accepted: 11/25/2011] [Indexed: 11/22/2022] Open
Abstract
Tumefactive fibroinflammatory lesion (TFIL) is a rare benign tumor in the head and neck region. We present a case of a 40-year-old female with a benign but progressive lesion of the infratemporal fossa, which was diagnosed as TFIL. Patient responded briefly to a course of steroid treatment but eventually showed progression and was unresponsive to further steroids. She was then treated with external beam radiation to a dose of 60 Gy in 30 fractions. After radiation a slow, gradual decrease in tumor size was noted over the course of years and she is free of disease after more than 11 years of follow-up. The major long-term side effect this patient developed was an expected unilateral radiation-induced retinopathy, due to the close proximity of the lesion to the orbit. The dilemma of treatment of benign disease with radiation with potential long-term complications is discussed and a review of the literature on TFIL is presented.
Collapse
Affiliation(s)
- Frank J P Hoebers
- Radiation Medicine Program, Princess Margaret Hospital, University Health Network and Radiation Oncology, University of Toronto, Ontario
| | | | | | | | | | | |
Collapse
|
4
|
Abstract
Gastrointestinal stromal tumors (GISTs) are uncommon mesenchymal tumors of the gastrointestinal tract. Up to one-third of GISTs are malignant with a high rate of metastasis. Surgical resection is the mainstay of care for patients with resectable disease. Imatinib mesylate, a selective tyrosine kinase inhibitor, is the current standard of care for GISTs that cannot be completely resected or in cases of metastatic GIST. Although often overlooked, radiation therapy is a viable option for select patients with GIST. We report the case of a patient with unresectable GIST who was treated with local radiotherapy and achieved long-term response. We also present a review of the literature regarding the use of radiotherapy in the treatment of GIST. GIST has been shown to be a radiosensitive tumor. Radiotherapy can offer long-term local control and should be considered in the adjuvant or palliative setting. The role of radiotherapy delivered concurrently with imatinib in the treatment of GIST may warrant further investigation.
Collapse
|
5
|
Koga N, Noguchi M, Moriya F, Ohshima K, Yoshitake N, Matsuoka K. A case of primary mucosa-associated lymphoid tissue lymphoma of the prostate. Rare Tumors 2009; 1:e55. [PMID: 21139934 PMCID: PMC2994450 DOI: 10.4081/rt.2009.e55] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2009] [Accepted: 11/30/2009] [Indexed: 11/23/2022] Open
Abstract
We report a case of primary mucosa-associated lymphoid tissue (MALT) lymphoma of the prostate. A 67-year-old man presented with urinary obstruction and an elevated prostate-specific antigen (PSA) level. A physical examination revealed mild prostate enlargement and no lymphadenopathy. A needle biopsy and immunohistochemical studies of the prostate were performed, which revealed marginal zone B-cell MALT-type lymphoma. A bone marrow aspiration and biopsy did not show involvement by lymphoma. Magnetic resonance imaging (MRI) of the abdomen and the pelvis revealed no lymphadenopathy or ascites. There was no involvement of other sites by lymphoma. The patient was diagnosed and staged as extranodal marginal zone B-cell MALT-type lymphoma of the prostate, low grade and stage I. The patient received external beam radiation therapy to the prostate with a total dose of 3600cGy in 22 fractions, and became free of disease within the following 15 months.
Collapse
|